Enzyme replacement therapy for Fabry disease: lessons from two α-galactosidase A orphan products and one FDA approval

ISSN： 1471-2598

Source： Expert Opinion on Biological Therapy, Vol.4, Iss.7, 2004-07, pp. : 1167-1176

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Production in yeast of α -galactosidase A, a lysosomal enzyme applicable to enzyme replacement therapy for Fabry disease

By Chiba Yasunori

Glycobiology, Vol. 12, Iss. 12, 2002-12 ,pp. : 821-828

Oxford University Press

Access to resources Recommend Favorite

Enzyme Replacement Therapy of Fabry Disease

By Clarke Joe T. R. Iwanochko R. Mark

Molecular Neurobiology, Vol. 32, Iss. 1, 2005-08 ,pp. : 43-50

Humana Press, Inc

Access to resources Recommend Favorite

Advances in the management of Anderson–Fabry disease:enzyme replacement therapy

By Thadhani Ravi Pastores Gregory M

Expert Opinion on Biological Therapy, Vol. 2, Iss. 3, 2002-03 ,pp. : 325-333

Informa Healthcare

Access to resources Recommend Favorite

Role of Ser-65 in the Activity of α-Galactosidase A: Characterization of a Point Mutation (S65T) Detected in a Patient with Fabry Disease

By Ishii S. Suzuki Y. Fan J-Q.

Archives of Biochemistry and Biophysics, Vol. 377, Iss. 2, 2000-05 ,pp. : 228-233

Elsevier

Access to resources Recommend Favorite

The Carboxyl Terminus of Coffee Bean α-Galactosidase Is Critical for Enzyme Activity

By Maranville E. Zhu A.

Archives of Biochemistry and Biophysics, Vol. 373, Iss. 1, 2000-01 ,pp. : 225-230

Elsevier

Access to resources Recommend Favorite